Recent News

AACR 2021: Overall Survival Update From IMmotion151 in Advanced Kidney Cancer

AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC

AACR 2021: Is Pembrolizumab Effective in Treating Advanced Cutaneous Squamous Cell Carcinoma?

AACR 2021: T-Cell Infusion Product Under Investigation in Resistant CLL

AACR 2021: Survival Outcomes by Treatment Response From IMvigor130 in Urothelial Cancer

Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML

AACR 2021: Combination Targeted Therapies Under Study in Resistant Kidney Cancer

Is Adjuvant Atezolizumab Safe and Effective in Muscle-Invasive Urothelial Cancer?

AACR 2021: Nivolumab Plus Ipilimumab in Biomarker-Selected Patients With Metastatic Prostate Cancer

ICER Releases Evidence Report on BCMA Therapies for Multiple Myeloma

Response to Induction Therapy and Ofatumumab Consolidation in Patients With CLL

Sacituzumab Govitecan-hziy Receives Regular FDA Approval for Triple-Negative Breast Cancer

Novel Agent Under Study in CLL: Dual Inhibitory Activity Reported

Daratumumab-Based Therapy for Myeloma: Patient-Reported Outcomes From CASTOR Trial

Adjuvant Durvalumab for Localized Urothelial Cancer

KEYNOTE-355 Update on Pembrolizumab in Triple-Negative Breast Cancer

IGLL5 Expression in Clear Cell Kidney Cancer: Potential Prognostic Biomarker?

FDA Approves First Cell-Based Gene Therapy for Multiple Myeloma

High-Risk CLL: GENUINE Trial of Ublituximab Plus Ibrutinib Versus Ibrutinib Alone

Novel Vaccine Under Study in Basal Cell Carcinoma

Early Access Treatment Protocol of Daratumumab in European and Russian Patients With Resistant Myeloma

BTK Inhibitor and Cerebral Invasive Aspergillosis: Case Report in CLL

Miami Breast Cancer Conference 2021: DESTINY-Breast01 Trial Update on Trastuzumab Deruxtecan-nxki

CLEAR Trial: Targeted Therapy Plus Immunotherapy in Advanced Renal Cell Carcinoma

Avelumab Plus Hypofractionated Radiotherapy for Resistant Multiple Myeloma

Cardiac Repolarization After Daratumumab Monotherapy for Smoldering Multiple Myeloma

KEYNOTE-365 Update on Pembrolizumab Plus Chemotherapy for Metastatic Prostate Cancer

Idecabtagene Vicleucel Under Study in Relapsed and Refractory Multiple Myeloma

Comparing Immunotherapy Regimens in Metastatic Kidney Cancer

Cemiplimab-rwlc Monotherapy and PD-L1 Expression in Advanced NSCLC

Margetuximab-cmkb Versus Trastuzumab in ERBB2-Positive Advanced Breast Cancer

Addition of Bevacizumab to Chemotherapy in Platinum-Sensitive Ovarian Cancer

GU Symposium 2021: Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab in Bladder Cancer

GU Symposium 2021: Radiotherapy Plus Pembrolizumab for Oligometastatic Kidney Cancer

GU Symposium 2021: Adding Pembrolizumab to Radium-223 for Metastatic Castration-Resistant Prostate Cancer

Blood Clots: New Adverse Event With First Infusion of Obinutuzumab for CLL?

GU Symposium 2021: Neoadjuvant Durvalumab Plus Chemotherapy in Muscle-Invasive Urothelial Carcinoma

Nivolumab as Neoadjuvant Therapy in High-Risk Clear Cell Renal Cell Carcinoma

WCLC 2020: 3-Year Survival Update on Pembrolizumab for Locally Advanced or Metastatic NSCLC

TCT 2021: Natural Killer Cell Therapy Under Study in Selected Patients With AML

GU Symposium 2021: Updated CheckMate 9ER Results on Nivolumab Plus Cabozantinib in Kidney Cancer

WCLC 2020: 5-Year Survival Update on Pembrolizumab Versus Docetaxel in NSCLC

WCLC 2020: Pembrolizumab Plus Chemotherapy for Metastatic NSCLC